Foresite Capital Management V, LLC Diversified Active

Name: Foresite Capital Management V, LLC Q3 2021 13F Filing | 13F Explorer
Creator: Foresite Capital Management V, LLC
Published: 2021-11-12

Location: West Hollywood, CA

CIK: 0001792206 · Show all filings

Period: Q3 2021 (← Previous) (Next →)

Filing Date: Nov 12, 2021

Total Value: $322M (100.0% shares, 0.0% debt)

Holdings (17)

— Somalogic, Inc. 20.5%

Value $66M Shares 5,326,472 Est. Cost $12.39 Unrealized —

CGEM Cullinan Oncology, Inc. 19.2%

Value $61.65M Shares 2,731,410 Est. Cost $40.60 Unrealized -34.1%

IVVD Adagio Therapeutics, Inc. 16.8%

Value $54.09M Shares 1,280,640 Est. Cost $37.11 Unrealized 0.0%

ACRS Aclaris Therapeutics, Inc. 7.0%

Value $22.65M Shares 1,258,243 Est. Cost $19.56 Unrealized -18.0%

— Kinnate Biopharma Inc. 6.3%

Value $20.14M Shares 875,001 Est. Cost $39.78 Unrealized —

QSI Quantum-Si Incorporated 6.1%

Value $19.53M Shares 2,342,061 Est. Cost $10.48 Unrealized -6.0%

HLTHQ Cue Health Inc. 4.3%

Value $13.79M Shares 1,167,782 Est. Cost $11.81 Unrealized —

NRIX Nurix Therapeutics, Inc. 4.2%

Value $13.53M Shares 451,522 Est. Cost $33.14 Unrealized -6.9%

— Gemini Therapeutics, Inc. 3.1%

Value $9.838M Shares 2,435,125 Est. Cost $13.55 Unrealized —

HIMS Hims & Hers Health, Inc. 2.5%

Value $7.969M Shares 1,056,922 Est. Cost $16.76 Unrealized -49.5%

PHVS Pharvaris N.V. 2.0%

Value $6.456M Shares 364,142 Est. Cost $31.46 Unrealized -45.6%

— 23andMe Holding Co. 2.0%

Value $6.342M Shares 700,000 Est. Cost $11.69 Unrealized —

— FS Development Corp. II 1.9%

Value $5.995M Shares 602,500 Est. Cost $9.96 Unrealized —

— Population Health Investment Co., Inc. 1.7%

Value $5.603M Shares 960,000 Est. Cost $10.45 Unrealized —

— Research Alliance Corp. II 1.5%

Value $4.925M Shares 500,000 Est. Cost $10.25 Unrealized —

MLTX Helix Acquisition Corp. 0.8%

Value $2.488M Shares 250,000 Est. Cost $11.37 Unrealized —

— Lucira Health, Inc. 0.2%

Value $760K Shares 485,000 Est. Cost $12.10 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
—	Somalogic, Inc.	5,326,472	$66M	20.5%	$12.39	—	COM CL A	83444K105
CGEM	Cullinan Oncology, Inc.	2,731,410	$61.65M	19.2%	$40.60	-34.1%	COM	230031106
IVVD	Adagio Therapeutics, Inc.	1,280,640	$54.09M	16.8%	$37.11	0.0%	COM	00534A102
ACRS	Aclaris Therapeutics, Inc.	1,258,243	$22.65M	7.0%	$19.56	-18.0%	COM	00461U105
—	Kinnate Biopharma Inc.	875,001	$20.14M	6.3%	$39.78	—	COM	49705R105
QSI	Quantum-Si Incorporated	2,342,061	$19.53M	6.1%	$10.48	-6.0%	COM CL A	74765K105
HLTHQ	Cue Health Inc.	1,167,782	$13.79M	4.3%	$11.81	—	COM	229790100
NRIX	Nurix Therapeutics, Inc.	451,522	$13.53M	4.2%	$33.14	-6.9%	COM	67080M103
—	Gemini Therapeutics, Inc.	2,435,125	$9.838M	3.1%	$13.55	—	COM	36870G105
HIMS	Hims & Hers Health, Inc.	1,056,922	$7.969M	2.5%	$16.76	-49.5%	COM CL A	433000106
PHVS	Pharvaris N.V.	364,142	$6.456M	2.0%	$31.46	-45.6%	COM	N69605108
—	23andMe Holding Co.	700,000	$6.342M	2.0%	$11.69	—	COM CL A	90138Q108
—	FS Development Corp. II	602,500	$5.995M	1.9%	$9.96	—	COM CL A	30318F100
—	Population Health Investment Co., Inc.	960,000	$5.603M	1.7%	$10.45	—	UNIT	G71716123
—	Research Alliance Corp. II	500,000	$4.925M	1.5%	$10.25	—	COM CL A	760873109
MLTX	Helix Acquisition Corp.	250,000	$2.488M	0.8%	$11.37	—	COM CL A	G4444C102
—	Lucira Health, Inc.	485,000	$760K	0.2%	$12.10	—	COM	54948U105